| 2.115 0.075 (3.68%) | 12-08 12:13 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.54 |
1-year : | 2.97 |
| Resists | First : | 2.18 |
Second : | 2.54 |
| Pivot price | 1.61 |
|||
| Supports | First : | 1.48 |
Second : | 1.05 |
| MAs | MA(5) : | 1.96 |
MA(20) : | 1.49 |
| MA(100) : | 1.3 |
MA(250) : | 0 | |
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 90.8  |
D(3) : | 93.9 |
| RSI | RSI(14): 82.6 |
|||
| 52-week | High : | 3.02 | Low : | 0.82 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GUTS ] has closed below upper band by 7.7%. Bollinger Bands are 83% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.12 - 2.12 | 2.12 - 2.13 |
| Low: | 1.93 - 1.94 | 1.94 - 1.95 |
| Close: | 2.03 - 2.04 | 2.04 - 2.05 |
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.
Mon, 08 Dec 2025
Rajagopalan, Fractyl Health CEO, buys $19998 in shares By Investing.com - Investing.com Nigeria
Mon, 29 Sep 2025
Fractyl Health stock price target lowered to $8 at H.C. Wainwright - Investing.com
Mon, 29 Sep 2025
Fractyl Health stock gains after pricing of $60M underwritten offering - MSN
Fri, 26 Sep 2025
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock - TradingView
Fri, 26 Sep 2025
$60 Million Stock Offering: Metabolic Therapeutics Company Fractyl Health Raises Capital at $1 Per Share - Stock Titan
Fri, 26 Sep 2025
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -50 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 1.3704e+008 (%) |
| Held by Institutions | 1.1134e+008 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 3000 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.32 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 291 % |
| Return on Equity (ttm) | 400 % |
| Qtrly Rev. Growth | -518.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -9.767e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -0.89 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 7.14e+006 |
| Forward Dividend | 6.85e+006 |
| Dividend Yield | 346602000% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|